Premium
Cost‐effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy‐resistant depression at secondary mental health care settings
Author(s) -
Sado Mitsuhiro,
Koreki Akihiro,
Ninomiya Akira,
Kurata Chika,
Mitsuda Dai,
Sato Yasunori,
Kikuchi Toshiaki,
Fujisawa Daisuke,
Ono Yutaka,
Mimura Masaru,
Nakagawa Atsuo
Publication year - 2021
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/pcn.13298
Subject(s) - pharmacotherapy , depression (economics) , cost effectiveness , medicine , cognitive behavioral therapy , mental health , randomized controlled trial , psychiatry , antidepressant , quality of life (healthcare) , collaborative care , cognitive therapy , anxiety , risk analysis (engineering) , nursing , economics , macroeconomics
Aim Pharmacotherapy is the primary treatment strategy in major depression. However, two‐thirds of patients remain depressed after the initial antidepressant treatment. Augmented cognitive behavioral therapy (CBT) for pharmacotherapy‐resistant depression in primary mental health care settings proved effective and cost‐effective. Although we reported the clinical effectiveness of augmented CBT in secondary mental health care, its cost‐effectiveness has not been evaluated. Therefore, we aimed to compare the cost‐effectiveness of augmented CBT adjunctive to treatment as usual (TAU) and TAU alone for pharmacotherapy‐resistant depression at secondary mental health care settings. Methods We performed a cost‐effectiveness analysis at 64 weeks, alongside a randomized controlled trial involving 80 patients who sought depression treatment at a university hospital and psychiatric hospital (one each). The cost‐effectiveness was assessed by the incremental cost‐effectiveness ratio (ICER) that compared the difference in costs and quality‐adjusted life years, and other clinical scales, between the groups. Results The ICERs were JPY −15 278 322 and 2 026 865 for pharmacotherapy‐resistant depression for all samples and those with moderate/severe symptoms at baseline, respectively. The acceptability curve demonstrates a 0.221 and 0.701 probability of the augmented CBT being cost‐effective for all samples and moderate/severe depression, respectively, at the threshold of JPY 4.57 million (GBP 30 000). The sensitivity analysis supported the robustness of our results restricting for moderate/severe depression. Conclusion Augmented CBT for pharmacotherapy‐resistant depression is not cost‐effective for all samples including mild depression. In contrast, it appeared to be cost‐effective for the patients currently manifesting moderate/severe symptoms under secondary mental health care.